Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum

被引:49
作者
Blazevic, Anela [1 ]
Hofland, Johannes [1 ]
Hofland, Leo J. [1 ]
Feelders, Richard A. [1 ]
de Herder, Wouter W. [1 ]
机构
[1] Erasmus Univ, Med Ctr, Erasmus MC,Sect Endocrinol, ENETS Ctr Excellence,Dept Internal Med, Rotterdam, Netherlands
关键词
neuroendocrine tumour; fibrosis; growth factors; targeted therapy; tumour microenvironment; GROWTH-FACTOR RECEPTOR; CONSENSUS GUIDELINES UPDATE; METASTATIC CARCINOID-TUMOR; SUBSTANCE-P; FACTOR-ALPHA; SEROTONIN SYNTHESIS; SIGNALING PATHWAYS; TAMOXIFEN THERAPY; STELLATE CELLS; MOUSE MODEL;
D O I
10.1530/ERC-17-0380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Small intestinal neuroendocrine tumours (SI-NETs) are neoplasms characterized by their ability to secrete biogenic amines and peptides. These cause distinct clinical pathology including carcinoid syndrome, marked by diarrhoea and flushing, as well as fibrosis, notably mesenteric fibrosis. Mesenteric fibrosis often results in significant morbidity by causing intestinal obstruction, oedema and ischaemia. Although advancements have been made to alleviate symptoms of carcinoid syndrome and prolong the survival of patients with SI-NETs, therapeutic options for patients with mesenteric fibrosis are still limited. As improved insight in the complex pathogenesis of mesenteric fibrosis is key to the development of new therapies, we evaluated the literature for known and putative mediators of fibrosis in SI-NETs. In this review, we discuss the tumour microenvironment, growth factors and signalling pathways involved in the complex process of fibrosis development and tumour progression in SI-NETs, in order to elucidate potential new avenues for scientific research and therapies to improve the management of patients suffering from the complications of mesenteric fibrosis.
引用
收藏
页码:R115 / R130
页数:16
相关论文
共 108 条
[101]  
Wulbrand U, 1998, EUR J CLIN INVEST, V28, P1038
[102]  
Wulbrand U, 2000, EUR J CLIN INVEST, V30, P729
[103]   Cellular and molecular mechanisms of fibrosis [J].
Wynn, T. A. .
JOURNAL OF PATHOLOGY, 2008, 214 (02) :199-210
[104]  
YANG K, 1983, CANCER-AM CANCER SOC, V51, P1918, DOI 10.1002/1097-0142(19830515)51:10<1918::AID-CNCR2820511027>3.0.CO
[105]  
2-Y
[106]   One hundred years after "Carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States [J].
Yao, James C. ;
Hassan, Manal ;
Phan, Alexandria ;
Dagohoy, Cecile ;
Leary, Colleen ;
Mares, Jeannette E. ;
Abdalla, Eddie K. ;
Fleming, Jason B. ;
Vauthey, Jean-Nicolas ;
Rashid, Asif ;
Evans, Douglas B. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) :3063-3072
[107]   Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours [J].
Zandee, Wouter T. ;
Kamp, Kimberly ;
van Adrichem, Roxanne C. S. ;
Feelders, Richard A. ;
de Herder, Wouter W. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 175 (05) :361-366
[108]   The role of β-Catenin, TGFβ3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids [J].
Zhang, PJ ;
Furth, EE ;
Goldblum, JR ;
Pasha, TL ;
Min, KW .
HUMAN PATHOLOGY, 2004, 35 (06) :670-674